WHO study finds no benefit from remdesivir on COVID-19 deaths, hospital stays

WHO study finds no benefit from remdesivir on COVID-19 deaths, hospital stays

The antiviral drug remdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays, according to a World Health Organization (WHO) clinical trial. The WHO Solidarity Trial examined the effects of four coronavirus different drug regimens: remdesivir; hydroxychloroquine; a combination of the anti-HIV drugs lopinavir and ritonavir; and interferon. ADVERTISEMENTAccording to WHO, none of the drugs had any noticeable impact on reducing mortality, the duration of hospitalization, or the need to ventilate patients. The study was billed as the world’s largest randomized control trial on COVID-19 therapeutics. The effect on mortality was not clear, and was not studied as part of the peer-reviewed, placebo-controlled clinical data.

About Us

When you want to outsmart the world, you turn to the facts. And the facts are in the science.

Subscribe to our newsletter!